JP7743309B2 - 同定されたアデノシンフィンガープリントを利用したがんの処置 - Google Patents

同定されたアデノシンフィンガープリントを利用したがんの処置

Info

Publication number
JP7743309B2
JP7743309B2 JP2021557643A JP2021557643A JP7743309B2 JP 7743309 B2 JP7743309 B2 JP 7743309B2 JP 2021557643 A JP2021557643 A JP 2021557643A JP 2021557643 A JP2021557643 A JP 2021557643A JP 7743309 B2 JP7743309 B2 JP 7743309B2
Authority
JP
Japan
Prior art keywords
alkyl
adenosine
cancer
group
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021557643A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527476A (ja
JP2022527476A5 (cg-RX-API-DMAC7.html
Inventor
エリザベス アンダーソン,エイミー
アショク,デビカ
エム. ディレンツォ,ダニエル
アール. ウドヤヴァール,アクシャタ
ジェイ. ウォルターズ,マシュー
ダブリュ. ヤング,スティーブン
Original Assignee
アーカス バイオサイエンシズ インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーカス バイオサイエンシズ インコーポレイティド filed Critical アーカス バイオサイエンシズ インコーポレイティド
Publication of JP2022527476A publication Critical patent/JP2022527476A/ja
Publication of JP2022527476A5 publication Critical patent/JP2022527476A5/ja
Application granted granted Critical
Publication of JP7743309B2 publication Critical patent/JP7743309B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021557643A 2019-03-29 2020-03-27 同定されたアデノシンフィンガープリントを利用したがんの処置 Active JP7743309B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962826728P 2019-03-29 2019-03-29
US62/826,728 2019-03-29
PCT/US2020/025242 WO2020205527A1 (en) 2019-03-29 2020-03-27 Treatment of cancer utilizing an identified adenosine fingerprint

Publications (3)

Publication Number Publication Date
JP2022527476A JP2022527476A (ja) 2022-06-02
JP2022527476A5 JP2022527476A5 (cg-RX-API-DMAC7.html) 2023-04-04
JP7743309B2 true JP7743309B2 (ja) 2025-09-24

Family

ID=72666937

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557643A Active JP7743309B2 (ja) 2019-03-29 2020-03-27 同定されたアデノシンフィンガープリントを利用したがんの処置

Country Status (8)

Country Link
US (2) US12310965B2 (cg-RX-API-DMAC7.html)
EP (1) EP3947463A4 (cg-RX-API-DMAC7.html)
JP (1) JP7743309B2 (cg-RX-API-DMAC7.html)
KR (1) KR20210144821A (cg-RX-API-DMAC7.html)
CN (1) CN113874397A (cg-RX-API-DMAC7.html)
AU (1) AU2020256098A1 (cg-RX-API-DMAC7.html)
CA (1) CA3135487A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020205527A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3823614A4 (en) 2018-07-18 2022-03-30 Arcus Biosciences, Inc. SOLID FORMS OF AN AZOLOPYRIMIDINE COMPOUND
ES3070946T3 (en) 2019-03-12 2026-06-18 Arcus Biosciences Inc Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
TWI821559B (zh) * 2019-04-28 2023-11-11 大陸商上海和譽生物醫藥科技有限公司 一種cd73抑制劑,其製備方法和應用
WO2021247188A1 (en) * 2020-06-05 2021-12-09 Bristol-Myers Squibb Company Cd73 antagonist potency assay and methods of use thereof
CA3179320A1 (en) 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof
WO2022178135A1 (en) * 2021-02-17 2022-08-25 Iteos Belguim Sa Compounds, compositions and methods of treatment thereof
KR20230158044A (ko) 2021-03-18 2023-11-17 남미 테라퓨틱스, 인크. 암의 치료에 유용한 A2aR 길항제 전구약물을 함유하는 제제화된 및/또는 공동-제제화된 리포솜 조성물 및 그의 방법
CA3231951A1 (en) * 2021-09-15 2023-03-23 Shuangni ZHAO Polymorph and application of pyrimidine derivative and pharmaceutically acceptable salt thereof
CN120091809A (zh) 2022-10-20 2025-06-03 艾库斯生物科学有限公司 Cd73化合物的冻干制剂

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017152085A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
JP2017534648A (ja) 2014-11-11 2017-11-24 メディミューン リミテッド 抗cd73抗体とa2a受容体阻害薬とを含む併用治療薬及びその使用
JP2019501223A (ja) 2016-01-08 2019-01-17 アーカス バイオサイエンシズ インコーポレイティド 5’ヌクレオチダーゼ,エクトのモジュレーター及びその使用

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002092020A2 (en) 2001-03-23 2002-11-21 The Burnham Institute Compositions and methods for modulating bone mineral deposition
US20030078232A1 (en) 2001-08-08 2003-04-24 Elfatih Elzein Adenosine receptor A3 agonists
JP2005516917A (ja) 2001-12-12 2005-06-09 アメリカ合衆国 細胞外アデノシン阻害剤およびアデノシン受容体阻害剤を用いて免疫応答および炎症を増強するための方法
WO2004079013A1 (en) * 2003-03-03 2004-09-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
US20090142347A1 (en) 2004-09-29 2009-06-04 The Burnham Institute For Medical Research Tissue-Nonspecific Alkaline Phosphatase (TNAP): a Therapeutic Target for Arterial Calcification
JP5238936B2 (ja) 2005-03-25 2013-07-17 ジーアイティーアール,インク. Gitr結合分子およびその使用
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
JP2009519236A (ja) 2005-11-30 2009-05-14 キャン−ファイト・バイオファーマ・リミテッド A3アデノシンレセプター抗体の治療的使用
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
PT2175884T (pt) 2007-07-12 2016-09-21 Gitr Inc Terapias de combinação empregando moléculas de ligação a gitr
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
EP3153526B1 (en) 2008-01-31 2020-09-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
MX356367B (es) 2008-12-09 2018-05-25 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t.
IN2015DN02826A (cg-RX-API-DMAC7.html) 2009-09-03 2015-09-11 Merck Sharp & Dohme
DK2510010T3 (en) 2009-12-10 2015-12-14 Hoffmann La Roche Antibodies that bind to human CSF1R extracellular domain 4 and their use
RU2617971C2 (ru) 2010-03-05 2017-04-28 Ф.Хоффманн-Ля Рош Аг Антитела против csf-1r человека и их применение
CN102918061B (zh) 2010-03-05 2016-06-08 霍夫曼-拉罗奇有限公司 针对人csf-1r的抗体及其用途
EP3943154A1 (en) 2010-05-04 2022-01-26 Five Prime Therapeutics, Inc. Antibodies that bind csf1r
EP2580243B1 (en) 2010-06-09 2019-10-16 Genmab A/S Antibodies against human cd38
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
WO2012031320A1 (en) * 2010-09-06 2012-03-15 Peter Maccallum Cancer Institute Cancer diagnostic
NZ729044A (en) 2010-09-09 2020-07-31 Pfizer 4-1bb binding molecules
WO2012085132A1 (en) 2010-12-22 2012-06-28 Orega Biotech Antibodies against human cd39 and use thereof
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
BR112014012819B1 (pt) 2011-11-28 2022-08-16 Merck Patent Gmbh Anticorpo anti-pd-l1 ou fragmento de ligação ao antígeno do mesmo e composição
MX356337B (es) 2011-12-15 2018-05-23 Hoffmann La Roche Anticuerpos contra csf-1r humano y sus usos.
MX2014008961A (es) 2012-02-06 2014-10-14 Genentech Inc Composiciones y metodos para utilizar inhibidores de csf1r.
AU2013222345B2 (en) 2012-02-22 2017-09-07 Sanford-Burnham Medical Research Institute Sulfonamide compounds and uses as TNAP inhibitors
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
KR20150018533A (ko) 2012-05-11 2015-02-23 파이브 프라임 테라퓨틱스, 인크. 콜로니 자극 인자 1 수용체(csf1r)에 결속하는 항체들에 의한 질병 상태의 치료 방법
AR091649A1 (es) 2012-07-02 2015-02-18 Bristol Myers Squibb Co Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos
CN107759690A (zh) 2012-08-31 2018-03-06 戊瑞治疗有限公司 用结合群落刺激因子1受体(csf1r)的抗体治疗病状的方法
US9307487B2 (en) 2013-08-30 2016-04-05 Qualcomm Incorporated Methods and systems for improved utilization of a wireless medium
EP3134411B1 (en) 2014-04-25 2021-06-30 Boehringer Ingelheim International GmbH Purine derivatives as cd73 inhibitors for the treatment of cancer
RS62003B2 (sr) 2014-11-10 2025-01-31 Medimmune Ltd Vezujući molekuli specifični za cd73 i njihove upotrebe
WO2017040930A2 (en) 2015-09-03 2017-03-09 The Trustees Of The University Of Pennsylvania Biomarkers predictive of cytokine release syndrome
EP3380519A1 (en) 2015-11-23 2018-10-03 Innate Pharma Cd39 vascular isoform targeting agents
WO2017098421A1 (en) 2015-12-08 2017-06-15 Glaxosmithkline Intellectual Property Development Limited Benzothiadiazine compounds
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives
WO2018067424A1 (en) 2016-10-03 2018-04-12 Arcus Biosciences, Inc. Inhibitors of adenosine 5'-nucleotidase
CN110022881B (zh) 2016-11-18 2023-05-02 艾库斯生物科学有限公司 Cd73介导的免疫抑制的抑制剂
KR102638592B1 (ko) 2016-12-22 2024-02-19 안텐진 테라퓨틱스 리미티드 엑토뉴클레오티다제 억제제 및 이의 용도
ES2985986T3 (es) * 2017-01-06 2024-11-08 Bicyclerd Ltd Conjugado biciclo para tratar el cáncer
MX389798B (es) 2017-01-20 2025-03-20 Arcus Biosciences Inc Azolopirimidina para el tratamiento de trastornos relacionados con el cáncer.
CA3045376C (en) 2017-01-24 2022-08-30 I-Mab Anti-cd73 antibodies and uses thereof
WO2018183635A1 (en) 2017-03-31 2018-10-04 Peloton Therapeutics, Inc. Cd73 inhibitors and uses thereof
US20190022096A1 (en) 2017-04-04 2019-01-24 Corvus Pharmaceuticals, Inc. Methods of treating cancer
WO2018187512A1 (en) 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods for treating cd73hi tumors
WO2018187484A1 (en) * 2017-04-04 2018-10-11 Corvus Pharmaceuticals, Inc. Methods of treating cancer
EP3618829B1 (en) 2017-05-05 2023-06-07 Arcus Biosciences, Inc. Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
WO2018208727A1 (en) 2017-05-08 2018-11-15 Eternity Bioscience Inc. Nucleoside and nucleotide analogues as cd73 inhibitors and therapeutic uses thereof
US11129841B2 (en) 2017-05-10 2021-09-28 Oric Pharmaceuticals, Inc. CD73 inhibitors
CN110636846B (zh) 2017-05-17 2023-05-16 艾库斯生物科学有限公司 用于治疗癌症相关疾病的喹唑啉吡唑衍生物
KR102770106B1 (ko) 2017-06-08 2025-02-21 블랙 벨트 테라퓨틱스 리미티드 Cd38 조정 항체
MX2019015885A (es) 2017-06-22 2020-09-10 Novartis Ag Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
US20200172628A1 (en) 2017-06-22 2020-06-04 Novartis Ag Antibody molecules to cd73 and uses thereof
CN107286146B (zh) 2017-07-05 2020-07-31 上海肇钰医药科技有限公司 作为腺苷a2a受体拮抗剂的4-氨基嘧啶衍生物及其用途
WO2019023635A1 (en) 2017-07-27 2019-01-31 Stingray Therapeutics, Inc. SUBSTITUTED 3 H-IMIDAZO (4,5-C) PYRIDINE AND 1H-PYRROLO (2,3-C) PYRIDINE SERIES OF A NOVEL ECTONUCLEOTIDE PYROPHOSPHATASE / PHOSPHODIESTERASE-1 (ENPP1) AND STIMULATOR FOR A GENE MODULATOR INTERFERON (STING) AS IMMUNOTHERAPEUTIC AGENTS AGAINST CANCER
JP7299873B2 (ja) 2017-08-16 2023-06-28 ブラック ベルト セラピューティクス リミテッド Cd38抗体
AU2018316521B2 (en) 2017-08-16 2025-01-30 Black Belt Therapeutics Limited CD38 modulating antibody
CA3080976A1 (en) 2017-11-06 2019-05-09 Corvus Pharmaceuticals, Inc. Adenosine pathway inhibitors for cancer treatment
CA3090922A1 (en) 2018-02-16 2019-08-22 Arcus Biosciences, Inc. Dosing with an azolopyrimidine compound
TWI702954B (zh) 2018-03-01 2020-09-01 美商美國禮來大藥廠 Cd73抑制劑
WO2019173682A1 (en) 2018-03-09 2019-09-12 Arcus Biosciences, Inc. Parenterally administered immune enhancing drugs
CA3096674A1 (en) 2018-04-12 2019-10-17 Bristol-Myers Squibb Company Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody
TW202012637A (zh) * 2018-04-24 2020-04-01 瑞典商阿斯特捷利康公司 治療癌症之方法
EP3823614A4 (en) 2018-07-18 2022-03-30 Arcus Biosciences, Inc. SOLID FORMS OF AN AZOLOPYRIMIDINE COMPOUND
AU2019312296B2 (en) 2018-07-27 2025-05-29 Arcus Biosciences, Inc. Pyridone A2R antagonists
ES3053198T3 (en) 2018-08-27 2026-01-20 Arcus Biosciences Inc Cd73 inhibitors
EP3863664A1 (en) 2018-10-11 2021-08-18 Pfizer Inc. Dosage regimen for tfpi antagonists
EP3893891A4 (en) 2018-12-13 2022-08-03 Arcus Biosciences, Inc. SOLID FORMS OF A CD73 INHIBITOR AND THEIR USE
ES3070946T3 (en) 2019-03-12 2026-06-18 Arcus Biosciences Inc Treatment of an oncogenene driven cancer having a kras or egfr mutation by decreasing adenosine production or antagonizing adenosine activation
CA3135487A1 (en) 2019-03-29 2020-10-08 Arcus Biosciences, Inc. Treatment of cancer utilizing an identified adenosine fingerprint
EP4084870A1 (en) * 2020-01-03 2022-11-09 Incyte Corporation Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy
US11633416B1 (en) 2020-03-06 2023-04-25 Arcus Biosciences, Inc. Oral formulations of CD73 compounds
CA3179320A1 (en) 2020-06-17 2021-12-23 Arcus Biosciences, Inc. Crystalline forms of a cd73 inhibitor and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017534648A (ja) 2014-11-11 2017-11-24 メディミューン リミテッド 抗cd73抗体とa2a受容体阻害薬とを含む併用治療薬及びその使用
JP2019501223A (ja) 2016-01-08 2019-01-17 アーカス バイオサイエンシズ インコーポレイティド 5’ヌクレオチダーゼ,エクトのモジュレーター及びその使用
WO2017152085A1 (en) 2016-03-04 2017-09-08 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Daniel DiRenzo et al.,'P35 Development of biomarkers to assess adenosine generation & activity in support of clinical trials conducted with the adenosine receptor antagonist AB928',JOURNAL FOR IMMUNOTHERAPY OF CANCER,2018年,vol. 6 (supple. 1),p. 18,DOI: 10.1186/S40425-018-0422-Y,P35

Also Published As

Publication number Publication date
JP2022527476A (ja) 2022-06-02
CN113874397A (zh) 2021-12-31
EP3947463A4 (en) 2022-12-21
CA3135487A1 (en) 2020-10-08
KR20210144821A (ko) 2021-11-30
AU2020256098A1 (en) 2021-10-28
US20220211701A1 (en) 2022-07-07
US20250375447A1 (en) 2025-12-11
US12310965B2 (en) 2025-05-27
EP3947463A1 (en) 2022-02-09
WO2020205527A1 (en) 2020-10-08

Similar Documents

Publication Publication Date Title
US20250375447A1 (en) Treatment of cancer utilizing an identified adenosine fingerprint
US20260115217A1 (en) Treatment of oncogene-driven cancers
Chan et al. IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion
Wu et al. Valproic acid upregulates NKG2D ligand expression through an ERK-dependent mechanism and potentially enhances NK cell-mediated lysis of myeloma
ES2918501T3 (es) Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
CA3163338A1 (en) Inhibitors of hif-2alpha
CN112004541A (zh) 肠道外给药的免疫增强药物
JP2022527133A (ja) マクロファージの活性を調節する方法
US20130017188A1 (en) Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
US11633416B1 (en) Oral formulations of CD73 compounds
JP7678032B2 (ja) がん療法において使用するためのデオキシシチジン誘導体又はデオキシウリジン誘導体
WO2017201036A1 (en) Stromal gene signatures for diagnosis and use in immunotherapy
US20200330595A1 (en) Pd-1 related cancer therapy
HK40058244A (en) Treatment of cancer utilizing an identified adenosine fingerprint
KR20250044292A (ko) 변형된 항-갈렉틴-9 항체 및 그의 용도
CN118043053A (zh) 治疗癌症的方法
US20250383345A1 (en) Methods and agents for determining patient status
HK40056396A (en) Treatment of oncogene-driven cancers
JP2025520098A (ja) Nsclcを処置するためのバイオマーカーおよび方法

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20220527

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220530

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20220531

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230327

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230327

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240321

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240611

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240726

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240924

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240924

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250425

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250908

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250910

R150 Certificate of patent or registration of utility model

Ref document number: 7743309

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150